A case of pulmonary pleomorphic carcinoma with preexisting interstitial pneumonia successfully treated with pembrolizumab

Pulmonary pleomorphic carcinoma is often refractory to chemotherapy and follows an aggressive clinical course. Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced lung cancer, and a few cases with pleomorphic carcinoma have been reported to show tumor shrinkage after th...

Descripción completa

Detalles Bibliográficos
Autores principales: Sako, Masahiro, Nokihara, Hiroshi, Kondo, Kensuke, Mitsuhashi, Atsushi, Ozaki, Ryohiko, Yabuki, Yohei, Abe, Akane, Yoneda, Hiroto, Ogino, Hirokazu, Otsuka, Kenji, Uehara, Hisanori, Nishioka, Yasuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8720630/
https://www.ncbi.nlm.nih.gov/pubmed/34859591
http://dx.doi.org/10.1111/1759-7714.14243
_version_ 1784625164253659136
author Sako, Masahiro
Nokihara, Hiroshi
Kondo, Kensuke
Mitsuhashi, Atsushi
Ozaki, Ryohiko
Yabuki, Yohei
Abe, Akane
Yoneda, Hiroto
Ogino, Hirokazu
Otsuka, Kenji
Uehara, Hisanori
Nishioka, Yasuhiko
author_facet Sako, Masahiro
Nokihara, Hiroshi
Kondo, Kensuke
Mitsuhashi, Atsushi
Ozaki, Ryohiko
Yabuki, Yohei
Abe, Akane
Yoneda, Hiroto
Ogino, Hirokazu
Otsuka, Kenji
Uehara, Hisanori
Nishioka, Yasuhiko
author_sort Sako, Masahiro
collection PubMed
description Pulmonary pleomorphic carcinoma is often refractory to chemotherapy and follows an aggressive clinical course. Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced lung cancer, and a few cases with pleomorphic carcinoma have been reported to show tumor shrinkage after therapy with ICIs. When treating patients with ICIs, patient selection is essential, and monitoring and management of immune‐related adverse events, including pneumonitis, are needed. We herein report a case of pulmonary pleomorphic carcinoma with preexisting interstitial pneumonia treated with pembrolizumab, antiprogrammed cell death 1 antibody. Our report highlights important considerations necessary when treating advanced pleomorphic carcinoma patients complicated with interstitial pneumonia. We also review the literature regarding the use of ICIs in such patients.
format Online
Article
Text
id pubmed-8720630
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-87206302022-01-07 A case of pulmonary pleomorphic carcinoma with preexisting interstitial pneumonia successfully treated with pembrolizumab Sako, Masahiro Nokihara, Hiroshi Kondo, Kensuke Mitsuhashi, Atsushi Ozaki, Ryohiko Yabuki, Yohei Abe, Akane Yoneda, Hiroto Ogino, Hirokazu Otsuka, Kenji Uehara, Hisanori Nishioka, Yasuhiko Thorac Cancer Case Reports Pulmonary pleomorphic carcinoma is often refractory to chemotherapy and follows an aggressive clinical course. Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced lung cancer, and a few cases with pleomorphic carcinoma have been reported to show tumor shrinkage after therapy with ICIs. When treating patients with ICIs, patient selection is essential, and monitoring and management of immune‐related adverse events, including pneumonitis, are needed. We herein report a case of pulmonary pleomorphic carcinoma with preexisting interstitial pneumonia treated with pembrolizumab, antiprogrammed cell death 1 antibody. Our report highlights important considerations necessary when treating advanced pleomorphic carcinoma patients complicated with interstitial pneumonia. We also review the literature regarding the use of ICIs in such patients. John Wiley & Sons Australia, Ltd 2021-12-03 2022-01 /pmc/articles/PMC8720630/ /pubmed/34859591 http://dx.doi.org/10.1111/1759-7714.14243 Text en © 2021 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Case Reports
Sako, Masahiro
Nokihara, Hiroshi
Kondo, Kensuke
Mitsuhashi, Atsushi
Ozaki, Ryohiko
Yabuki, Yohei
Abe, Akane
Yoneda, Hiroto
Ogino, Hirokazu
Otsuka, Kenji
Uehara, Hisanori
Nishioka, Yasuhiko
A case of pulmonary pleomorphic carcinoma with preexisting interstitial pneumonia successfully treated with pembrolizumab
title A case of pulmonary pleomorphic carcinoma with preexisting interstitial pneumonia successfully treated with pembrolizumab
title_full A case of pulmonary pleomorphic carcinoma with preexisting interstitial pneumonia successfully treated with pembrolizumab
title_fullStr A case of pulmonary pleomorphic carcinoma with preexisting interstitial pneumonia successfully treated with pembrolizumab
title_full_unstemmed A case of pulmonary pleomorphic carcinoma with preexisting interstitial pneumonia successfully treated with pembrolizumab
title_short A case of pulmonary pleomorphic carcinoma with preexisting interstitial pneumonia successfully treated with pembrolizumab
title_sort case of pulmonary pleomorphic carcinoma with preexisting interstitial pneumonia successfully treated with pembrolizumab
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8720630/
https://www.ncbi.nlm.nih.gov/pubmed/34859591
http://dx.doi.org/10.1111/1759-7714.14243
work_keys_str_mv AT sakomasahiro acaseofpulmonarypleomorphiccarcinomawithpreexistinginterstitialpneumoniasuccessfullytreatedwithpembrolizumab
AT nokiharahiroshi acaseofpulmonarypleomorphiccarcinomawithpreexistinginterstitialpneumoniasuccessfullytreatedwithpembrolizumab
AT kondokensuke acaseofpulmonarypleomorphiccarcinomawithpreexistinginterstitialpneumoniasuccessfullytreatedwithpembrolizumab
AT mitsuhashiatsushi acaseofpulmonarypleomorphiccarcinomawithpreexistinginterstitialpneumoniasuccessfullytreatedwithpembrolizumab
AT ozakiryohiko acaseofpulmonarypleomorphiccarcinomawithpreexistinginterstitialpneumoniasuccessfullytreatedwithpembrolizumab
AT yabukiyohei acaseofpulmonarypleomorphiccarcinomawithpreexistinginterstitialpneumoniasuccessfullytreatedwithpembrolizumab
AT abeakane acaseofpulmonarypleomorphiccarcinomawithpreexistinginterstitialpneumoniasuccessfullytreatedwithpembrolizumab
AT yonedahiroto acaseofpulmonarypleomorphiccarcinomawithpreexistinginterstitialpneumoniasuccessfullytreatedwithpembrolizumab
AT oginohirokazu acaseofpulmonarypleomorphiccarcinomawithpreexistinginterstitialpneumoniasuccessfullytreatedwithpembrolizumab
AT otsukakenji acaseofpulmonarypleomorphiccarcinomawithpreexistinginterstitialpneumoniasuccessfullytreatedwithpembrolizumab
AT ueharahisanori acaseofpulmonarypleomorphiccarcinomawithpreexistinginterstitialpneumoniasuccessfullytreatedwithpembrolizumab
AT nishiokayasuhiko acaseofpulmonarypleomorphiccarcinomawithpreexistinginterstitialpneumoniasuccessfullytreatedwithpembrolizumab
AT sakomasahiro caseofpulmonarypleomorphiccarcinomawithpreexistinginterstitialpneumoniasuccessfullytreatedwithpembrolizumab
AT nokiharahiroshi caseofpulmonarypleomorphiccarcinomawithpreexistinginterstitialpneumoniasuccessfullytreatedwithpembrolizumab
AT kondokensuke caseofpulmonarypleomorphiccarcinomawithpreexistinginterstitialpneumoniasuccessfullytreatedwithpembrolizumab
AT mitsuhashiatsushi caseofpulmonarypleomorphiccarcinomawithpreexistinginterstitialpneumoniasuccessfullytreatedwithpembrolizumab
AT ozakiryohiko caseofpulmonarypleomorphiccarcinomawithpreexistinginterstitialpneumoniasuccessfullytreatedwithpembrolizumab
AT yabukiyohei caseofpulmonarypleomorphiccarcinomawithpreexistinginterstitialpneumoniasuccessfullytreatedwithpembrolizumab
AT abeakane caseofpulmonarypleomorphiccarcinomawithpreexistinginterstitialpneumoniasuccessfullytreatedwithpembrolizumab
AT yonedahiroto caseofpulmonarypleomorphiccarcinomawithpreexistinginterstitialpneumoniasuccessfullytreatedwithpembrolizumab
AT oginohirokazu caseofpulmonarypleomorphiccarcinomawithpreexistinginterstitialpneumoniasuccessfullytreatedwithpembrolizumab
AT otsukakenji caseofpulmonarypleomorphiccarcinomawithpreexistinginterstitialpneumoniasuccessfullytreatedwithpembrolizumab
AT ueharahisanori caseofpulmonarypleomorphiccarcinomawithpreexistinginterstitialpneumoniasuccessfullytreatedwithpembrolizumab
AT nishiokayasuhiko caseofpulmonarypleomorphiccarcinomawithpreexistinginterstitialpneumoniasuccessfullytreatedwithpembrolizumab

Ejemplares similares